Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESTED: Dolutegravir vs Efavirenz in HIV-1-Infected Pregnant Women
NCT03048422Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2018; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03048422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048422.